Prelude Therapeutics (PRLD) Corporate presentation summary

Leadership and expertise

• Executive team includes experienced leaders with backgrounds at major pharma and biotech firms.

• Track record includes development of approved drugs such as Jakafi, Tabrecta, Olumiant, and others.

Pipeline and discovery engine

• Advancing a pipeline focused on mutant-selective JAK2V617F inhibitors, KAT6A selective degraders, and mCALR-targeted DACs.

• PRT12396 (JAK2V617F inhibitor) is in Phase 1 for myeloproliferative neoplasms (MPNs); PRT13722 (KAT6A degrader) to enter Phase 1 in HR+ breast cancer in Q4 2026.

• Proprietary degrader payloads available for licensing and additional partnerships in place.

JAK2V617F program highlights

• PRT12396 is a highly selective JAK2V617F JH2 inhibitor with >200x selectivity over JAK1/TYK2 and a clean kinase profile.

• Demonstrates significant disease-modifying potential in preclinical MPN models, with a ~10x therapeutic window over toxicity.

• Phase 1 trial enrolling for MF and PV, with endpoints including hematologic response and allele burden reduction.

• Exclusive option agreement with Incyte provides $35M upfront, $25M equity, and up to $875M in milestones plus royalties.